|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Yao H, Zhang Z, Xiao Z, et al:
Identification of metastasis associated proteins in human lung
squamous carcinoma using two-dimensional difference gel
electrophoresis and laser capture microdissection. Lung Cancer.
65:41–48. 2009. View Article : Google Scholar
|
|
3
|
Hanagiri T, Baba T, So T, et al: Time
trends of surgical outcome in patients with non-small cell lung
cancer. J Thorac Oncol. 5:825–829. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim KY, Ahn JH and Cheon HG: Apoptotic
action of peroxisome proliferator-activated receptor-γ activation
in human non-small cell lung cancer is mediated via proline
oxidase-induced reactive oxygen species formation. Mol Pharmacol.
72:674–685. 2007.
|
|
5
|
Lazzaro D, Price M, de Felice M and Di
Lauro R: The transcription factor TTF-1 is expressed at the onset
of thyroid and lung morphogenesis and in restricted regions of
foetal brain. Development. 113:1093–1104. 1991.PubMed/NCBI
|
|
6
|
Ikeda K, Clark JC, Shaw-White JR, Stahlman
MT, Boutell CJ and Whitset JA: Gene structure and expression of
human thyroid transcription factor-1 in respiratory epithelial
cells. J Biol Chem. 270:8108–8114. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maeda Y, Hunter TC, Loudy DE, Davé V,
Schreiber V and Whitsitt JA: PARP-2 interacts with TTF-1 and
regulates expression of surfactant protein-B. J Biol Chem.
28:9600–9606. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou H, Morotti RA, Profitt SA, Langston
C, Wert SE, Whitsett JA and Greco MA: Expression of thyroid
transcription factor-1, surfactant proteins, type I cell-associated
antigen, and Clara cell secretory protein in pulmonary hypoplasia.
Pediatr Dev Pathol. 4:364–371. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zamecnik J and Kodet R: Value of thyroid
transcription factor-1 and surfactant apoprotein A in the
differential diagnosis of pulmonary carcinomas: a study of 109
cases. Virchows Arch. 440:353–361. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pelosi G, Fraggeta F, Pasini F, et al:
Immunoreactivity for thyroid transcription factor-1 in stage I
non-small carcinomas of the lung. Am J Surg Pathol. 25:363–372.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kaufmann O and Dietel M: Thyroid
transcription factor-1 is the superior immunohistochemical marker
for pulmonary adenocarcinomas and large cell carcinomas compared to
surfactant proteins A and B. Histopathology. 36:8–16. 2000.
View Article : Google Scholar
|
|
12
|
Berghmans T, Paesmans M, Mascaux C, et al:
Thyroid transcription factor 1 - a new prognostic factor in lung
cancer: a meta-analysis. Ann Oncol. 17:1673–1676. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Myong NH: Thyroid transcription factor-1
(TTF-1) expression in human lung carcinomas: its prognostic
implication and relationship with expressions of p53 and Ki-67
proteins. J Korean Med Sci. 18:494–500. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCT method. Methods.
25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fujita J, Ohtsuki Y, Bandoh S, et al:
Expression of thyroid transcription factor-1 in 16 human lung
cancer cell lines. Lung Cancer. 39:31–36. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang P, Zuo H, Nakamura Y, Nakamura M,
Wakasa T and Kakudo K: Immunohistochemical analysis of
thyroid-specific transcription factors in thyroid tumors. Pathol
Int. 56:240–245. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
van der Kallen CJ, Spierings DC, Thijssen
JH, Blankenstein MA and de Bruin TW: Disrupted co-ordination of
Pax8 and thyroid transcription factor-1 gene expression in a
dedifferentiated rat thyroid tumor cell line derived from FRTL-5. J
Endocrinol. 150:377–382. 1996.PubMed/NCBI
|
|
18
|
Puppin C, D'Elia AV, Pellizzari L, et al:
Thyroid-specific transcription factors control Hex promoter
activity. Nucleic Acids Res. 31:1845–1852. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ndoye A, Merlin JL, Leroux A, et al:
Enhanced gene transfer and cell death following p53 gene transfer
using photochemical internalisation of glucosylated PEI-DNA
complexes. J Gene Med. 6:884–894. 2004. View Article : Google Scholar
|
|
20
|
Pataer A, Fanale MA, Roth JA, Swisher SG
and Hunt KK: Induction of apoptosis in human lung cancer cells
following treatment with amifostine and an adenoviral vector
containing wild-type p53. Cancer Gene Ther. 13:806–814. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fukazawa T, Maeda Y, Durbin ML, et al:
Pulmonary adenocarcinoma-targeted gene therapy by a cancer- and
tissue-specific promoter system. Mol Cancer Ther. 6:244–252. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Weir BA, Woo MS, Getz G, et al:
Characterizing the cancer genome in lung adenocarcinoma. Nature.
450:893–898. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yatabe Y, Mitsudomi T and Takahashi T:
TTF-1 expression in pulmonary adenocarcinomas. American J Surg
Pathol. 26:767–773. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Winslow MM, Dayton TL, Verhaak RG, et al:
Suppression of lung adenocarcinoma progression by Nkx2-1. Nature.
473:101–104. 2011. View Article : Google Scholar : PubMed/NCBI
|
